Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloperidone LAI in schizophrenia
NCT06961968Phase 3Recruiting
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- May 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of iloperidone in schizophrenia, sponsored by Vanda Pharmaceuticals Inc.. Started May 2025; status: recruiting.
02
Drugs
iloperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06961968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06961968.